The Part the Cloud + Bill Gates Partnership
Bill Gates and Part the Cloud have partnered to accelerate research to explore specific areas of neurodegeneration that contribute to the development of Alzheimer's and dementia, including how brain cells use energy and fuel, how brain cells remove waste and debris to avoid protein clumping, and how blood supply in the brain is maintained.
Gates joined the Alzheimer's Association Part the Cloud global research program by funding a $10 million award. The Alzheimer's Association, working through Part the Cloud, has raised over $20 million, doubling the total research investment to $60 million. This partnership will propel 19 high-risk, high-reward research projects aimed at potential new treatments and devices for Alzheimer's and dementia. Across all of these areas of research, the importance of the immune system and inflammation in the brain will continue to be the focus and priority of research funding by the Part the Cloud program. Learn more about this partnership.
Research Can Change the Future
Finding a way to slow the progression, effectively prevent and ultimately cure Alzheimer's disease is one of the greatest healthcare challenges of our time. An estimated 50 million people are living with Alzheimer's and dementia worldwide — a number that can only be changed for future generations through research.
Part the Cloud is committed to funding novel research ideas to determine if they will be effective treatments for the millions of people affected by Alzheimer's. Learn more about applying for a Part the Cloud grant.
While the vast increase in our understanding of Alzheimer's has led to the identification of promising targets for new therapies, the process of developing and testing potential therapies is long and complex, taking years and substantial resources. Many promising research ideas stall due to lack of funding.
Most grants support middle and latter clinical trials, but there are few funding sources to support the earlier phase studies needed to test drug treatments in people. Part the Cloud addresses this critical gap, supporting early phase clinical studies and helping accelerate the transition of findings from the laboratory into possible therapies.
Part the Cloud has generated over $60 million in funding for Alzheimer's research, making it possible for the Alzheimer's Association to award 59 additional research grants during this time. These awards span a variety of targets in Alzheimer's disease research and fall under the leadership of some of the nation's most prestigious scientists and universities.
View a copy of our 2020 Impact Report detailing the accomplishments that we have made.
